FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ELP4-FREM1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ELP4-FREM1
FusionPDB ID: 26337
FusionGDB2.0 ID: 26337
HgeneTgene
Gene symbol

ELP4

FREM1

Gene ID

26610

158326

Gene nameelongator acetyltransferase complex subunit 4FRAS1 related extracellular matrix 1
SynonymsAN|AN2|C11orf19|PAX6NEB|PAXNEB|dJ68P15A.1|hELP4BNAR|C9orf143|C9orf145|C9orf154|MOTA|TILRR|TRIGNO2
Cytomap

11p13

9p22.3

Type of geneprotein-codingprotein-coding
Descriptionelongator complex protein 4PAX6 neighbor gene proteinelongation protein 4 homologFRAS1-related extracellular matrix protein 1extracellular matrix protein QBRICK
Modification date2020031320200321
UniProtAcc

Q96EB1

Main function of 5'-partner protein: FUNCTION: Component of the RNA polymerase II elongator complex, a multiprotein complex associated with the RNA polymerase II (Pol II) holoenzyme, and which is involved in transcriptional elongation (PubMed:11714725, PubMed:11818576, PubMed:16713582). The elongator complex catalyzes formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (PubMed:29332244). {ECO:0000269|PubMed:11714725, ECO:0000269|PubMed:11818576, ECO:0000269|PubMed:16713582, ECO:0000303|PubMed:29332244}.

Q5H8C1

Main function of 5'-partner protein: FUNCTION: Extracellular matrix protein that plays a role in epidermal differentiation and is required for epidermal adhesion during embryonic development. {ECO:0000250}.
Ensembl transtripts involved in fusion geneENST idsENST00000350638, ENST00000379163, 
ENST00000395934, 
ENST00000380894, 
ENST00000486223, ENST00000380880, 
ENST00000380881, ENST00000422223, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 12 X 7=12604 X 5 X 4=80
# samples 144
** MAII scorelog2(14/1260*10)=-3.16992500144231
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/80*10)=-1
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ELP4 [Title/Abstract] AND FREM1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ELP4 [Title/Abstract] AND FREM1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ELP4(31625454)-FREM1(14816869), # samples:1
Anticipated loss of major functional domain due to fusion event.ELP4-FREM1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ELP4-FREM1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ELP4-FREM1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ELP4-FREM1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneELP4

GO:0006357

regulation of transcription by RNA polymerase II

11818576



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:31625454/chr9:14816869)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ELP4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across FREM1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000350638ELP4chr1131625454-ENST00000422223FREM1chr914816869-74126883546811548
ENST00000350638ELP4chr1131625454-ENST00000380881FREM1chr914816869-74126883546811548
ENST00000350638ELP4chr1131625454-ENST00000380880FREM1chr914816869-46826883546811549
ENST00000379163ELP4chr1131625454-ENST00000422223FREM1chr914816869-73956711546641549
ENST00000379163ELP4chr1131625454-ENST00000380881FREM1chr914816869-73956711546641549
ENST00000379163ELP4chr1131625454-ENST00000380880FREM1chr914816869-46656711546641549
ENST00000395934ELP4chr1131625454-ENST00000422223FREM1chr914816869-7384660746531548
ENST00000395934ELP4chr1131625454-ENST00000380881FREM1chr914816869-7384660746531548
ENST00000395934ELP4chr1131625454-ENST00000380880FREM1chr914816869-4654660746531549

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000350638ENST00000422223ELP4chr1131625454-FREM1chr914816869-0.0001184340.9998815
ENST00000350638ENST00000380881ELP4chr1131625454-FREM1chr914816869-0.0001184340.9998815
ENST00000350638ENST00000380880ELP4chr1131625454-FREM1chr914816869-0.0004967490.99950325
ENST00000379163ENST00000422223ELP4chr1131625454-FREM1chr914816869-0.0001216380.9998784
ENST00000379163ENST00000380881ELP4chr1131625454-FREM1chr914816869-0.0001216380.9998784
ENST00000379163ENST00000380880ELP4chr1131625454-FREM1chr914816869-0.0005281580.99947184
ENST00000395934ENST00000422223ELP4chr1131625454-FREM1chr914816869-0.000116620.9998834
ENST00000395934ENST00000380881ELP4chr1131625454-FREM1chr914816869-0.000116620.9998834
ENST00000395934ENST00000380880ELP4chr1131625454-FREM1chr914816869-0.0004980260.99950194

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ELP4-FREM1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ELP4chr1131625454FREM1chr914816869660218PEKISSTLKVEPWYQHDGTEVLQDDL
ELP4chr1131625454FREM1chr914816869671219PEKISSTLKVEPWYQHDGTEVLQDDL
ELP4chr1131625454FREM1chr914816869688218PEKISSTLKVEPWYQHDGTEVLQDDL

Top

Potential FusionNeoAntigen Information of ELP4-FREM1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ELP4-FREM1_31625454_14816869.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ELP4-FREM1chr1131625454chr914816869688HLA-B15:17STLKVEPWY0.96040.9389514
ELP4-FREM1chr1131625454chr914816869688HLA-B57:01STLKVEPWY0.95910.9817514
ELP4-FREM1chr1131625454chr914816869688HLA-B58:01STLKVEPWY0.93570.9531514
ELP4-FREM1chr1131625454chr914816869688HLA-B15:16STLKVEPWY0.80990.8038514
ELP4-FREM1chr1131625454chr914816869688HLA-B39:01WYQHDGTEVL0.86490.95381222
ELP4-FREM1chr1131625454chr914816869688HLA-B48:01WYQHDGTEVL0.76040.92851222
ELP4-FREM1chr1131625454chr914816869688HLA-B39:13WYQHDGTEVL0.75680.9761222
ELP4-FREM1chr1131625454chr914816869688HLA-C15:04STLKVEPWY0.48930.9293514
ELP4-FREM1chr1131625454chr914816869688HLA-B39:08WYQHDGTEVL0.77710.96891222
ELP4-FREM1chr1131625454chr914816869688HLA-B39:05WYQHDGTEVL0.76190.9481222
ELP4-FREM1chr1131625454chr914816869688HLA-B48:03WYQHDGTEVL0.44090.80041222
ELP4-FREM1chr1131625454chr914816869688HLA-B57:10STLKVEPWY0.95910.9817514
ELP4-FREM1chr1131625454chr914816869688HLA-B57:04STLKVEPWY0.94120.7493514
ELP4-FREM1chr1131625454chr914816869688HLA-C15:09STLKVEPWY0.48930.9293514
ELP4-FREM1chr1131625454chr914816869688HLA-C14:02WYQHDGTEV0.14190.97061221
ELP4-FREM1chr1131625454chr914816869688HLA-C14:03WYQHDGTEV0.14190.97061221
ELP4-FREM1chr1131625454chr914816869688HLA-C14:03WYQHDGTEVL0.95650.97781222
ELP4-FREM1chr1131625454chr914816869688HLA-C14:02WYQHDGTEVL0.95650.97781222
ELP4-FREM1chr1131625454chr914816869688HLA-B39:02WYQHDGTEVL0.86650.97431222
ELP4-FREM1chr1131625454chr914816869688HLA-B15:30WYQHDGTEVL0.85460.96081222
ELP4-FREM1chr1131625454chr914816869688HLA-B15:73WYQHDGTEVL0.84110.97681222
ELP4-FREM1chr1131625454chr914816869688HLA-B39:11WYQHDGTEVL0.75370.9421222
ELP4-FREM1chr1131625454chr914816869688HLA-B15:09WYQHDGTEVL0.70.90051222
ELP4-FREM1chr1131625454chr914816869688HLA-B40:12WYQHDGTEVL0.44090.80041222
ELP4-FREM1chr1131625454chr914816869688HLA-B40:21WYQHDGTEVL0.4340.87231222
ELP4-FREM1chr1131625454chr914816869688HLA-B40:49WYQHDGTEVL0.39260.79051222

Top

Potential FusionNeoAntigen Information of ELP4-FREM1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ELP4-FREM1_31625454_14816869.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ELP4-FREM1chr1131625454chr914816869688DRB1-0338EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB1-0338VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB1-0462EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0101EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0101VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0101KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0101PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0104EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0104VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0104KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0104PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0105EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0105VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0105KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0105PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0108EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0108VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0108KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0108PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0109EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0109VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0109KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0109PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0111EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0111VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0111KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0111PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0112EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0112VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0112KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0112PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0113EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0113VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0113KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0113PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0114EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0114VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0114KVEPWYQHDGTEVLQ823
ELP4-FREM1chr1131625454chr914816869688DRB3-0114PWYQHDGTEVLQDDL1126
ELP4-FREM1chr1131625454chr914816869688DRB3-0209EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0209VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0216EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0216VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0221EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0221VEPWYQHDGTEVLQD924
ELP4-FREM1chr1131625454chr914816869688DRB3-0303EPWYQHDGTEVLQDD1025
ELP4-FREM1chr1131625454chr914816869688DRB3-0303VEPWYQHDGTEVLQD924

Top

Fusion breakpoint peptide structures of ELP4-FREM1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9468TLKVEPWYQHDGTEELP4FREM1chr1131625454chr914816869688

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ELP4-FREM1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9468TLKVEPWYQHDGTE-7.51697-7.62877
HLA-B14:023BVN9468TLKVEPWYQHDGTE-5.12156-6.16466
HLA-B52:013W399468TLKVEPWYQHDGTE-6.73631-6.84811
HLA-B52:013W399468TLKVEPWYQHDGTE-3.86442-4.90752
HLA-A24:025HGA9468TLKVEPWYQHDGTE-8.03129-9.07439
HLA-A24:025HGA9468TLKVEPWYQHDGTE-7.53242-7.64422
HLA-B44:053DX89468TLKVEPWYQHDGTE-5.0744-6.1175
HLA-B44:053DX89468TLKVEPWYQHDGTE-4.16933-4.28113
HLA-A02:016TDR9468TLKVEPWYQHDGTE-5.87905-5.99085
HLA-A02:016TDR9468TLKVEPWYQHDGTE-2.17247-3.21557

Top

Vaccine Design for the FusionNeoAntigens of ELP4-FREM1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ELP4-FREM1chr1131625454chr9148168691221WYQHDGTEVCTGGTATCAACATGATGGAACTGAAGT
ELP4-FREM1chr1131625454chr9148168691222WYQHDGTEVLCTGGTATCAACATGATGGAACTGAAGTTCT
ELP4-FREM1chr1131625454chr914816869514STLKVEPWYTTCAACTCTCAAAGTAGAACCCTGGTA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ELP4-FREM1chr1131625454chr9148168691025EPWYQHDGTEVLQDDAGAACCCTGGTATCAACATGATGGAACTGAAGTTCTTCAGGATGA
ELP4-FREM1chr1131625454chr9148168691126PWYQHDGTEVLQDDLACCCTGGTATCAACATGATGGAACTGAAGTTCTTCAGGATGACCT
ELP4-FREM1chr1131625454chr914816869823KVEPWYQHDGTEVLQCAAAGTAGAACCCTGGTATCAACATGATGGAACTGAAGTTCTTCA
ELP4-FREM1chr1131625454chr914816869924VEPWYQHDGTEVLQDAGTAGAACCCTGGTATCAACATGATGGAACTGAAGTTCTTCAGGA

Top

Information of the samples that have these potential fusion neoantigens of ELP4-FREM1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
CHOLELP4-FREM1chr1131625454ENST00000350638chr914816869ENST00000380880TCGA-ZU-A8S4-01A

Top

Potential target of CAR-T therapy development for ELP4-FREM1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ELP4-FREM1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ELP4-FREM1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource